TY - JOUR AU - Serrano, C. AU - Bauer, S. AU - Gómez-Peregrina, D. AU - Kang, Y-K AU - Jones, R. L. AU - Rutkowski, P. AU - Mir, O. AU - Heinrich, M. C. AU - Tap, W. D. AU - Newberry, K. AU - Grassian, A. AU - Shi, H. AU - Bialick, S. AU - Schöffski, P. AU - Pantaleo, M. A. AU - von Mehren, M. AU - Trent, J. C. AU - George, S. TI - Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. JO - Annals of oncology VL - 34 IS - 7 SN - 0923-7534 CY - Amsterdam [u.a. PB - Elsevier M1 - DKFZ-2023-00835 SP - 615-625 PY - 2023 N1 - 2023 Jul;34(7):615-625 AB - The current treatment paradigm of imatinib-resistant metastatic gastrointestinal stromal tumor (GIST) does not incorporate KIT/PDGFRA genotypes in therapeutic drug sequencing, except for PDGFRA exon 18-mutant GIST that are indicated for avapritinib treatment. Here, ctDNA sequencing was used to analyze plasma samples prospectively collected in the phase III VOYAGER trial to understand how the KIT/PDGFRA mutational landscape contributes to tyrosine-kinase inhibitor (TKI) resistance and to determine its clinical validity and utility.VOYAGER (N=476) compared avapritinib with regorafenib in patients with KIT/PDGFRA-mutant GIST previously treated with imatinib and 1 or 2 additional TKIs (NCT03465722). KIT/PDGFRA ctDNA mutation profiling of plasma samples at baseline and end-of-treatment was assessed with 74-gene Guardant360® CDx. Molecular subgroups were determined and correlated with outcomes.386/476 patients with KIT/PDGFRA-mutant tumors underwent baseline (pre-trial treatment) ctDNA analysis; 196 received avapritinib, and 190 received regorafenib. KIT and PDGFRA mutations were detected in 75.1 KW - Avapritinib (Other) KW - GIST (Other) KW - KIT (Other) KW - PDGFRA (Other) KW - ctDNA (Other) KW - regorafenib (Other) LB - PUB:(DE-HGF)16 C6 - pmid:37105265 DO - DOI:10.1016/j.annonc.2023.04.006 UR - https://inrepo02.dkfz.de/record/275647 ER -